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DOI: 10.1039/c0ay00705fPeptidomics plays an important role in clinical proteomics and disease-associated biomarker discovery.
It has exhibited mounting potential in early noninvasive diagnosis, prognosis, and treatment evaluation
of diseases. This article presents an introduction of peptidomics, the entire peptidomic workflows for
serum and urine samples, and a brief overview of recent works in this area. The review is designed to
enable researchers to find the most suited strategy for their peptidome studies.Introduction
The term ‘peptidomics’, initially mentioned by four groups, was
introduced in the beginning of this century.1–4 This concept was
derived from genomics and proteomics. Peptidomics refers to the
qualitative, quantitative, and functional description of the whole
biologically active peptides in a cell, tissue, or organism.5 The
peptidome is the low-molecular-weight (LMW) subset of the
proteomes, including peptides and small proteins with molecular
weights ranging from 0.5 to 15 kDa.6 From the view of molecular
weights, the peptidome studies can fill the gap between proteo-
mics and metabonomics.
Peptides in the peptidome can be divided into two categories
(as shown in Fig. 1). One category is the bioactive peptides shed
from all cell types in the microenvironment. They may serve as
reporters for cell-to-cell communications, such as hormones and
cytokines.7 The other is the peptide fragments cleaved by
enzymes resulting from in vivo resident proteins which couldFig. 1 The peptidome hypothesis. The term ‘peptidome’ refers to two
types of in vivo peptides.
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This journal is ª The Royal Society of Chemistry 2011reflect biological enzymatic states of individuals.8–10 Body fluids
are rich in disease-specific peptide and protein candidates, which
are the primary resource for peptidome studies. Peptidome
biomarkers in human body fluids are expected to forecast
disease, diagnose various disorders, guide clinical therapy, and
monitor medicine response.
The analysis of body fluids for clinical diagnosis can reduce the
need of invasive tests. Serum and urine samples, which could be
obtained easily and repeatedly, are sufficient to provide valuable
information about dynamic variations within human body. The
blood circulating around nearly every organ including tumors
keeps direct and close contact with all cells and tissues and
contains large quantities of proteolytical peptides, proteins, and
protein fragments.1 Recent studies have shown that the serum
peptidome has been a tempting field.11–13 Urine, except for the
noninvasive feature, has other appealing properties such as the
low concentration of proteins and easiness for enrichment.14
Among body fluids, urine is especially attractive for biomarker
discovery in urological diseases.15–18Experimental methods
As so-called little sister or daughter of proteomics,6 analytical
process of peptidomics is quite similar to the common strategy of
proteomics. The peptidome workflow of biofluid samples usually
contains sample storage, preparation, separation, detection, data
mining, and biomarker identification and quantification. Several
aspects have to be taken into account during the development of
a method for peptidome studies. Hereby, to follow a standard-
ized protocol is necessary since it could provide a guideline for
performing highly efficient peptidome studies and achieving
accuracy results. The main technical procedures are introduced
here.1 Sample storage and preparation
Since the peptidomics focuses on endogenous peptides, sample
storage becomes an important work which influences final































































View Onlinecollected to clot at room temperature for 1 hour and then
centrifuged at the speed ranging from 1000 to 4000g for about 10
minutes. The clotting time and temperature show great influences
on serum qualities, whereas freeze–thaw cycles are not so
important.7 Serum (supernatant) samples are supplemented with
a cocktail of protease inhibitors,19 and then kept in aliquots at
80 C until utilized. Before being processed for extraction,
thawed serum samples are centrifuged at more than 10 000g for
15 min to exclude most of the lipids and insoluble components.
First-void morning urine samples should be kept at 80 C
after immediate collection for further peptide extraction. Quin-
tana et al.17 added protease inhibitors into each sample in order
to avoid proteolysis. Before utilization, samples are thawed at
room temperature for 15 min and centrifuged at approximately
1000g to 1500g, 4 C for 10 minutes to remove cell debris.
Ahmad et al.20 suggested not to store samples over 20 C in
order to prevent protein degradation. For long-term storage,
keeping in liquid nitrogen is preferred. All samples should be
collected consecutively, but not at distinct times to reduce the
storage-induced noise in high-throughput experiments.2 Extraction of peptides
Polypeptides are required to be separated from high molecular
weight (HMW) proteins, other organic compounds, and inor-
ganic components before analysis. With the wide dynamic range
of protein abundance and the interference of highly abundant
HMW proteins, the extraction and enrichment of polypeptides in
complex biological mixtures remain a challenging task. For
peptidomic analysis, the basic separation mechanism is the
molecular weight difference between proteins and peptides.
Serum, which contains proteins in a large dynamic range, is more
complex than the urine sample. Depletion of HMW proteins in
serum seems especially critical. Nevertheless, the inherent inter-
ferences in urine samples such as pH and salt concentration also
yield great background and noise. Theodorescu et al.18 believed
that urinary peptides are stable and will not undergo significant
proteolysis within several hours of collection. In contrast, acti-
vation of proteases in blood samples is often associated with
collection.
In order to achieve high extraction yield of LMW proteins and
peptides, various works have aimed at depletion of high-abun-
dance proteins. So far, many methods and technologies have
been applied to extract peptides and small proteins, such as
organic solvent precipitation,21 ultrafiltration,13 magnetic
beads,22 solid-phase extraction (SPE),23 affinity removal
column,24 strong cation exchange (SCX),14 etc. Snap-freezing
extraction has also been used, which could lower the protein
degradation and reduce the sample complexity.25 Furthermore,
restricted access materials (RAM) have been proved to be
effective and convenient to exclude HWM proteins and retain
LMW proteins and peptides in the pores.26 These materials are
based on the mechanisms of size exclusion chromatography
(SEC) and reversed phase (RP) adsorption. A novel mixed mode
of strong cation exchange/size exclusion capillary trap column
was developed to selectively extract peptides for the injection into
nano liquid chromatography.12 C-8-functionalized magnetic
nanoparticles,27 C-18 absorbent,28 nanoporous silica particles,29
derivatized mesoporous silica beads,30 ZnO–poly(methyl774 | Anal. Methods, 2011, 3, 773–779methacrylate) nanobeads,31 mesoporous silica chips,32 and self-
assembled TiO2 nanocrystal clusters
33 have been reported with
various characteristics. It is also reported that 2,5-dihydroxy-
benzoic acid allows the effective extraction of endogenous
peptides from tissues and the extracts can be stored without
frozen for a long time.34 Appropriate sample extraction methods
lead to the simplification and acceleration of the whole process
for peptidome analysis. Collectively, all these measures are
dedicated to identify LMW proteins and peptides. Each method
has its own strength and weakness. A most appropriate method
can be chosen from all these approaches according to their effi-
ciency of HMW protein depletion and LMW protein (peptide)
extraction. Here we focus on three convenient and widely used
methods, which are precipitation, ultrafiltration, and SPE.
Organic solvent precipitation has been employed to remove
HMW proteins.35 The addition of organic precipitants into
protein solution results in the precipitation of denatured
proteins, while peptides and LMW proteins could dissolve in the
high concentration organic solvents. Polson et al.36 interpreted
the process in two aspects. The dielectric constant of the protein
mixtures decreases when organic solvent precipitants are added
in, which makes the close attraction of charged molecules. On the
other hand, organic solvent displaces the ordered water mole-
cules around proteins. Hydrophobic interactions lead to protein
aggregation and precipitation. Especially, acetonitrile (ACN)
depletion was considered as the most effective and reproducible
approach. Kawashima et al.37 developed a method called
differential solubilization to extract peptides and LMW proteins
in the subnanomolar range; four biomarker candidates of colon
cancer were successfully discovered. However, precipitation
presents some limitations, such as non-specific depletion and
dilution of the sample. On the whole, the organic-precipitation
method is rapid, simple, and cheap.26
Ultrafiltration is realized by filtering the sample using
a membrane of a defined molecular weight cut-off (MWCO)
based on size exclusion mechanism. Greening and Simpson38
compared four commercial filter membranes whose nominal
MWCOs are similar, and chose the one with the best overall
performance for optimization. Zougman et al.39 explored
centrifugal ultrafiltration to analyse the peptidome of the cere-
brospinal fluid (CSF) samples; the result shows the confident
identification of 563 peptide forms. Although some drawbacks
have been encountered in mass transfer efficiency, flux limitation,
and simultaneous concentration of LMW contaminants, ultra-
filtration is a simple and routine method.
In order to get high enriching capacity, SPE has been widely
used in order to desalt and retain peptides. Various materials in
different mechanisms are used, which contain nonpolar (e.g. C-8,
C-18), polar (e.g. –CN, –NH2), and other affinity materials (e.g.
PS–DVB adsorbent).40 In recent applications, SPE is often
combined with other pre-separation techniques, such as novel
RP-SCX SPE precolumn14 and SCX/SEC-RAM online extrac-
tion,12 for the maximum coverage of peptidome. A study has
been carried out to evaluate the performance of SPE, ultrafil-
tration, ACN precipitation, and SEC; and the result indicates
that SPE exhibits the best peptide recovery.23 Collectively, SPE
presents a good capability of HMW protein depletion and LMW
protein (peptide) extraction, but a relatively lower reproduc-































































View Online3 Fractionation (separation)
Though peptides have been extracted from serum and urine
samples, they cannot be injected immediately into the mass
spectrometer due to the high complexity of the extracted sample.
For example, the peptides with the same amino acid composition
but different sequences generate the same mass spectrometry
(MS) spectra of molecular ions, when MS is used as the analysing
technique.41 Therefore further separation steps are essential and
even indispensable for the biomarker identification and discovery.
The one-dimensional (1D)42 and two-dimensional (2D) gel elec-
trophoresis (GE),43 which have sprung up over the last decades,
could provide the staining intensity of a particular protein spot for
quantification purposes. However, with the popularity of MS, the
signal intensity from the mass spectrometer for quantification is
preferred rather than the protein staining intensity used in the
gels.44 Many ongoing quantification methods are contributed to
the gel-free separation approaches. Thus, qualification and
quantification by GE will not be covered here.
Capillary electrophoresis (CE) is gaining increasing attention.
It offers unique advantages of high resolving power, high effi-
ciency, short analysis time, low sample consumption, and low
running cost. However, CE requires an adequate ionic strength
buffer, which is not compatible with ESI-MS. Therefore three
types of interfaces have been developed to solve this problem:
sheathless, liquid junction, and sheathflow interfaces.5 Now CE
has become an established technique in biofluid analyses,
particularly for the extraction from biologic samples.45–48 Wang
et al.49 have explored the offline coupling of CE to MS analysis
and optimized the separation, deposition, and subsequent MS
detection processes. In their experiment, the use of 2,5-dihy-
droxybenzoic acid as a multi-functional agent offers a simplified
and improved protocol for the enhanced extraction and
improved spectral quality of neuropeptide analysis.
As a hyphenated technique for MS, liquid chromatography
(LC) remains the most popular method for peptide separation. It
overcomes the disadvantage of the limited loading capacity in CE
technique. In general, up to 100 microlitre quantities can be
loaded into an LC column, whereas a CE can only be filled with
a maximum of 1 mL, commonly around 50 nL.50 Bakun et al.51
have successfully used LC-MS system to study the global
peptides for two sets of serum samples from healthy individuals
and patients.
Owing to the high complexity of peptidome, 1D separation is
insufficient in resolving power. Therefore, multidimensional
separation technology with different mechanisms has been
developed for the in-depth analysis of biosamples.52 Tenorio-
Laranga et al.25 have combined 2D-RPLC to MS to identify the
peptides in rat brain. Theoretically, more than two dimensional
separations can be applied in order to achieve high resolution
and large peak capacity. However, the relatively long period of
analysis time and complicated data processing could hamper its
use for high-throughput profiling of clinical samples.534 Detection and identification
Mass spectrometer is an accurate and sensitive device which
enables simultaneous analysis of a great number of peptides and
proteins.54,55 However, characterization of endogenous bioactiveThis journal is ª The Royal Society of Chemistry 2011peptides is challenging due to the high complexity of biofluid
samples. Detection of numerous fragments necessitates the
development of high-throughput, accurate, and sensitive mass
spectrometer. Meanwhile the development of MS has been
accelerated by the genome project and the proteomic research.
Currently MS is regarded as a gold standard for protein
profiling.56 Matrix-assisted laser desorption/ionization
(MALDI) and electrospray ionization (ESI) are two commonly
used soft ionization techniques which can effectively change solid
or liquid samples into gaseous ions without excessive frag-
ments.57
MALDI is mostly used as an offline interface from LC or CE
to MS. It is considered as a useful tool to detect biological
samples owing to the ability of analysing complex samples and its
high tolerance of salt concentration. Integrated LC-ESI-MS
platforms are preferred for the analyses of complex biofluid
samples. High performance liquid chromatography has been
widely used with ESI-MS for bioactive peptide profiling, mainly
due to the possibility and availability of online coupling.55 In
addition, surface-enhanced laser desorption/ionization time of
flight mass spectrometry (SELDI-TOFMS), which combines the
pre-selection of peptides and proteins on a specific surface with
a time-of-flight mass spectrometer, can detect multiple proteins
and peptides in biological samples. This technique has success-
fully been applied for disease biomarker discovery in tissue and
blood samples for various cancers.58–60
For peptidomic analysis, the key challenges for MS are
sensitivity, mass accuracy, and the ability to generate informa-
tion-rich fragments with tandem MS.61 There are four commonly
used types of mass analysers: quadrupole, time-of-flight, ion
trap, and Fourier transform ion cyclotron resonance. These
analysers are usually put together in tandem to strengthen their
superiorities.
Quadrupole (Q) has a low resolving power but offers high
stability when acting as a mass analyser; it is particularly useful
as a transmission device or a collision cell when operated in rf-
only mode. A time-of-flight (TOF) analyser offers good sensi-
tivity and high resolving power. The MALDI source is normally
coupled with the TOF analyser.62,63 The hybrid system (Q-TOF)
is quite popular, in which a quadrupole system is coupled
orthogonally to a TOF. It exhibits an increased mass accuracy
and resolution, as well as the MS/MS function.64 Ion traps are
capable of storing a number of ions and selecting specific ions for
single- or multiple-stage fragmentation. Moreover, QTRAP (Q-
q-Q/LIT), which combines triple quadrupole with linear ion trap,
offers the superior capability of specific modification detec-
tions.65 Fourier transform ion cyclotron resonance (FTICR) MS
also traps the ions. It has the highest mass accuracy and resolving
power among all types of mass analysers, and also provides MS/
MS fragmentation function. Chen et al.66 made the evaluation of
three commonly used types of MALDI instruments for neuro-
peptide expression analysis, including MALDI TOF/TOF,
MALDI FTICR and MALDI LTQ Orbitrap mass spectrome-
ters. The result shows that the MALDI LTQ Orbitrap provides
the best overall performance in mass accuracy, dynamic range,
and spectral resolution when it is used with high energy colli-
sional dissociation for complete fragmentation.
In order to determine the amino acid sequence of a specific































































View OnlineThe collision-induced dissociation fragmentation technique is
incorporated in basically all types of tandem MS. It is based on
electron transfer and cleavage of the precursor ions through
collisions with inert gas molecules in the collision cell. New
fragmentation techniques, such as electron capture dissociation
(ECD) and electron transfer dissociation (ETD), have been
developed. They are capable of offering explicit fragmental
spectra for the determination of amino acid sequence, which are
particularly useful in localization of modifications and complete
profiling of amino acid sequence.575 Quantitative evaluation
The advent of high-throughput MS-based proteomics has
created a strong demand for compatible quantitative analysis
methodologies. Clinical diagnosis further promotes the devel-
opment of quantification methods. As a result, various tech-
niques have emerged for gel-free quantitative analyses of
proteomics and peptidomics samples. Each of these methods
comes along with certain strengths and drawbacks. Researchers
often excessively rely on the software such that the validity of
results could not be correctly assessed. Quantification methods
can be commonly divided into three main categories: stable
isotope labeling, label-free methods, and multiple reaction
monitoring (MRM).44
5.1 Stable isotope labeling. For quantitative analysis with
good accuracy, isotope-labeling technique is the most widely
used approach. It has been applied to a variety of cell systems
and biofluid samples. Stable isotope labeling is a rapidly evolving
field. Many kinds of tag labeling methods have been developed.
Isotope-labeling techniques can be used either after protein
extraction with chemical labeling, or in cell culture with meta-
bolic incorporation. Among these methods, the most useful
techniques are iTRAQ (Isobaric tags for relative and absolute
quantitative) and ICAT (Isotope coded affinity tags).13 The
quantitation is introduced using differential isotopic tags to label
two or more (up to eight for iTRAQ 8-plex reagent) sets of
extracted peptides prior to LC separation. All samples are then
pooled and processed with the regular strategy following the
standardized peptidomic procedures. The relative amount of
each peptide can be determined by the relative intensities of
‘light’ or ‘heavy’ forms of peptides.
Other than iTRAQ and ICAT, deuterium is employed to
compare the peptide levels in extracts from two sets of samples.67
Moreover, the proteolytic 18O method relies on the differentia-
tion of two groups using different stable isotopes of oxygen.68
The quantitative capability is introduced during the proteolytic
digestion of the LMW proteins in ‘light’ or ‘heavy’ water. The 16O
or 18O atoms are incorporated into the C-terminus of the digested
peptides and the samples are pooled together and identified/
quantified using MS. The 18O method is relatively simple and
universal that it can be applied to any proteins as well as
peptides. Miyagi and Rao69 gave an overview of the proteolytic
18O-labeling technique including its history, the advantages and
disadvantages of this method, and its biological applications.
Fricker et al.70 illustrated the differences between proteomics and
peptidomics, and introduced the 18O labeling approaches of
endogenous peptides in neuroendocrine tissues. Robinson et al.71776 | Anal. Methods, 2011, 3, 773–779devised an 18O labeling strategy to study endogenous proteinase
activities in complex biological samples. This approach could
monitor peptide products with an unbiased and global detection
and characterization.5.2 Label-free approach. As the name implies, label-free
quantification could provide quantitative information without
using any form of labeling reagents. Due to the high cost of
isotopic labeling reagents, a label-free strategy has been
a reasonable alternative when numerous samples need to be
analysed. Peptidomic analysis prefers label-free methods, owing
to the simplicity of experimental protocols, though it is a bit
difficult to quantify small changes in the peptide level without
isotopic labeling.72 In general, highly precise and accurate mass
spectra are vital to the label-free quantification as well as the
high-resolution mass spectrometer to complex mixture analyses.
Rossbach et al.73 explored a label-free MS-based approach to
identify and quantify a variety of endogenous peptides from rat.
They suggested some of the identified peptides as conceivable
biomarker candidates for the drug-induced withdrawal behavior.
Kultima et al.74 determined endogenous peptides by label-free
relative quantification method and investigated 10 different
normalization methods on peptide data generated with LC-MS.
The result indicated that the best normalization method could
decrease the median standard deviation by 43% on average
compared with non-normalized method.5.3 MRM. Multiple reaction monitoring, also called selected
reaction monitoring, is an emerging technology that partly
overcomes the shortcomings of shotgun workflows. MRM
usually exploits in a triple quadrupole mass spectrometer; the
first and the third quadrupoles are to specifically select a pre-
defined precursor and one fragment of it, whereas the second
quadrupole acts as a collision cell for fragmentation. It has the
potential to reliably quantify analytes of low abundance in
complex mixtures with high sensitivity and specificity.75 The
serum extracts after ACN-depletion were fractioned by a nano-
flow LC/tandem MS and quantified by the MRM method by
Kay et al.21 This method shows a viable alternative to the
immunochemistry-based protein-depletion techniques
commonly used for removing high abundance proteins from
serum prior to MS-based proteomic analyses. Cirulli et al.65
exploited the IMAC (immobilized metal affinity chromato-
graphy) modified protocol combined with MRM-based triple
quadrupole scan modes to achieve a sensitive and rapid analysis
for phosphopeptide identification and characterization.Data processing and bioinformatics
1 Data mining and statistical analysis
The increasing popularity of gel-free proteomic technologies has
promoted the development of appropriate statistical methods.
Nowadays chemometrics has become an essential method and
contributed greatly to the development and flourish of the
‘-omics’ fields such as metabonomics76 and proteomics.77
In reality, biological MS data are extremely complex and hard































































View Onlinealgorithms in order to obtain statistical interpretation. The
algorithms reduce the raw data to a new set of variables which
are statistically correlated to the original data. The few major
components could account for most of the variations in the
data. Multivariate clustering analysis, allowing to obtain
a highest discrimination ratio, is usually performed to dis-
tinguish among the categories of objectives on their peptide
profiles.
There are many data mining strategies for processing and
profiling of multivariate data. All these strategies fall into two
categories. The first is unsupervised methods, among which the
most classical approach is the principal component analysis
(PCA). PCA as an unsupervised method explains the maximum
variation between samples; it utilizes a bilinear decomposition
approach without information of any groupings.78 The principal
components are calculated from numerous original data, and
they maximize the variability of the original predictors across
samples.79 Supervised methods, the second category, are suitable
when the inner-group variance dominates over intra-group
variance, including mainly support vector machines (SVM)59 and
partial least-squares discriminant analysis (PLS-DA).80 The
SVM method classifies data based upon their maximal separa-
tion using a three-dimensional hyperplane. This method could
minimize the over-training of the data, but is unable to provide
levels of confidence to any classification.58 PLS-DA clusters two
defined groups in the maximum separation.81 It is done by a PLS
regression based on PCA analysis. Thus, mapping of data using
PLS-DA model that sharpens the separation is applied to
investigate the differences between two sets of samples and
further to predict classification of unknown samples. Orthogonal
PLS (O-PLS) is an extension of PLS. It selects peaks with
a significant differing median between groups of samples and
works well in metabonomics82 and proteomics83 currently.
Forshed et al.83 illustrated that O-PLS models could give the
most potential and robust biomarker candidates with the
removal of structure noise. Skytt et al.84 set up an optimized
platform for SELDI-TOFMS and O-PLS data analysis to search
biomarkers of the clinical significance in prostate cancer, which
allows the verification of peptidomic markers for early diagnosis
of the cancer.
The process of internal and external cross-validation should be
performed to validate the model obtained from the classification
analysis and avoid false estimates and overfitting.80 The data in
peptidome may be divided into two sets, a training set and
a validation set. The training data are used to form multivariate
models for feature selection and training the classifier to derive
a model that is then applied on the validation set.50 After cross-
validation, the models become much reliable and could well
interpret the variations. The biomarker candidates are then
evaluated using appropriate methods, such as receiver operating
characteristic curve (ROC), that offer prediction accuracy of
individual markers.85
Another statistical method to verify biomarker candidates is to
calculate the p-value between each group using the homosce-
dastic Student’s t-test. P-Values interpret the level of significance
for discrimination between two defined groups.86 As criteria, the
significant biomarker will be confirmed only if it has a p-value of
less than 0.05 in the t-test. Candidates with p-value greater than
0.05 are usually eliminated.13This journal is ª The Royal Society of Chemistry 20112 Peptidomic characterization
Mass spectra are analysed using search engines. The most
commonly used search engines are Mascot (http://www.
matrixscience.com), SeQuest algorithms (http://www.thermo.
com), X!Tandem (http://www.thegpm.org), OMSSA (http://
pubchem.ncbi.nlm.nih.gov/omssa), and MS-Fit (http://
prospector.ucsf.edu).19 There are several peptide sequencing
information databases such as non-redundant NCBI (http://
www.ncbi.nlm.nih.gov), SwePep (http://www.swepep.org),
Erop-Moscow (http://erop.inbi.ras.ru), PeptideDB (http://
www.peptides.be), Peptidome (http://www.peptidome.jp), Pep-
Bank (http://pepbank.mgh.harvard.edu), IPI human protein
database (http://www.ebi.ac.uk/IPI), and so on.24,44,87 For
instance, SwePep is a gathering of information on a number of
endogenous peptides, and the validation is performed by
comparing the fragmentation between the two spectra.88,89 Pep-
Bank, created in 2007, is a free database of peptides compiled
from sequence text-mining and public peptide data sources.90
This database includes biological and clinical applications, which
is especially useful for the prediction of the binding partners of
biologically interesting peptides.
3 Biomarker validation
Following the steps of biomarker discovery and characteristics,
validation should be taken into account according to the pro-
teomic patterns. High false-discovery rate hampers the veracity
of biomarker candidates.91 Perfect biomarkers could discrimi-
nate disease from healthy controls. It becomes obvious that
separate markers would not be sufficient, but a combination of
well-selected markers could be meaningful.48 Therefore, specific,
sensitive, and high-throughput immunoassays are primarily
employed to verify the biomarkers. Since suitable and high-
quality antibodies with sufficient specificity and sensitivity are
expensive and hard to optimize,91 a straightforward validation
method has emerged recently. A multiplexed MRM approach
coupled with stable isotope dilution provides an alternative assay
method.92 Meanwhile, problems of the reproducibility and
transferability of MRM assays still need to be overcome.
Conclusion and future perspectives
In recent years, protein separation and detection technologies
have reached a matured level such that proteomic processes of
biological samples can be analysed reproducibly and accu-
rately.53 Based on the successful experiences of proteomics,
researchers could avoid detours in peptidome studies. Many
methods and techniques applied to proteomics are readily
applicable to the peptidome. Although peptidome is a subfield of
proteome, it has some inherent characteristics. First of all, due to
its low molecular weight and low concentration, the peptidome
could be assessed without tryptic digestions. Secondly, the pep-
tidome aims at the identification of endogenous peptides; the
inactive peptides derived from proteolysis are not its research
objectives. Finally, peptidomics focuses on the sequence infor-
mation of the peptides, whereas proteomics emphasizes the
protein identifications.
There is an urgent need for discovering valid biomarkers to































































View Onlineattention has been paid to clinical peptidomics and biomarker
discovery. The peptidome researches of tissues, CSF, serum, and
urine samples are simultaneously ongoing. While tissues and
CSF could offer relatively higher specificity and clinical rele-
vance, serum and urine are still more attractive with higher
availability and a lower factor of invasiveness.93
Discovery of biomarkers that are of prognostic and diagnostic
relevance has been a major focus of proteomic research during
the past decade. Nowadays peptidomics is an evolving tool to
understand the pathogenesis of disease process and improve
clinical outcomes. In particular, many attempts have been made
to identify and verify peptide biomarkers in biofluids with pro-
teomic patterns. We hope that this review will serve as a basis for
peptidomic protocol and provide some insights towards
biomarker discovery. It can be foreseen that a platform of pep-
tidomic biomarker validation will be applied for routine
healthcare and guideline to diseases in the future.Acknowledgements
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